- Home
- TORO vs SPRO Comparison
TORO vs SPRO Comparison
Compare TORO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- SPRO
- Stock Information
- Founded
- TORO 2022
- SPRO 2013
- Country
- TORO Cyprus
- SPRO United States
- Employees
- TORO N/A
- SPRO N/A
- Industry
- TORO Marine Transportation
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- SPRO Health Care
- Exchange
- TORO Nasdaq
- SPRO Nasdaq
- Market Cap
- TORO 55.1M
- SPRO 45.7M
- IPO Year
- TORO N/A
- SPRO 2017
- Fundamental
- Price
- TORO $2.54
- SPRO $0.78
- Analyst Decision
- TORO
- SPRO Buy
- Analyst Count
- TORO 0
- SPRO 4
- Target Price
- TORO N/A
- SPRO $5.00
- AVG Volume (30 Days)
- TORO 22.9K
- SPRO 104.3K
- Earning Date
- TORO 03-18-2025
- SPRO 03-21-2025
- Dividend Yield
- TORO N/A
- SPRO N/A
- EPS Growth
- TORO N/A
- SPRO N/A
- EPS
- TORO 0.99
- SPRO 0.06
- Revenue
- TORO $80,626,531.00
- SPRO $106,455,000.00
- Revenue This Year
- TORO N/A
- SPRO N/A
- Revenue Next Year
- TORO N/A
- SPRO N/A
- P/E Ratio
- TORO $0.90
- SPRO $12.03
- Revenue Growth
- TORO 52.03
- SPRO 37.01
- 52 Week Low
- TORO $2.25
- SPRO $0.74
- 52 Week High
- TORO $6.06
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- TORO 36.37
- SPRO 39.16
- Support Level
- TORO $2.46
- SPRO $0.74
- Resistance Level
- TORO $2.62
- SPRO $0.82
- Average True Range (ATR)
- TORO 0.10
- SPRO 0.03
- MACD
- TORO -0.01
- SPRO 0.00
- Stochastic Oscillator
- TORO 27.59
- SPRO 33.05
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.